J.

lease type a plus sign (+) inside this box	+

PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032

11/5/01

Date

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No.	032580.0045.CIP			
First Inventor	ALAN H. OSTROF			

CURRENT WAVEFORMS FOR ANTI-TACHYCARDIA Title PACING FOR A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR

EL675946346US Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) 7. 1. Computer Program (Appendix) (Submit an original and a duplicate for fee processing) Nucleotide and/or Amino Acid Sequence Submission 2. Applicant claims small entity status. See 37 CFR 1.27. (if applicable, all necessary) Specification a. Computer Readable Form (CRF) 3. [Total Pages 91] (preferred arrangement set forth below) Specification Sequence Listing on: - Descriptive title of the invention b. Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or Statement Regarding Fed sponsored R & D ii. paper Reference to sequence listing, a table, or a computer program listing appendix C. Statements verifying identity of above copies Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) Assignment Papers (cover sheet & document(s)) 9. - Detailed Description - Claim(s) 37 CFR 3.73(b) Statement Power of 10. (when there is an assignee) Attorney - Abstract of the Disclosure English Translation Document (if applicable) [Total Sheets 11] 4. Drawing(s) (35 U.S.C. 113) 11. Copies of IDS Information Disclosure [Total Pages 12. Oath or Declaration Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) 13. Preliminary Amendment a. Return Receipt Postcard (MPEP 503) Copy from a prior application (37 CFR 1.63 (d)) 14. b. (for continuation/divisional with Box 18 completed) (Should be specifically itemized) DELETION OF INVENTOR(S) Certified Copy of Priority Document(s) (if foreign 15. Signed statement attached deleting inventor(s) named in the pnor application, see 37 CFR 1.63(d)(2) and 1.33(b). priority is claimed) Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 Application Data Sheet. See 37 CFR 1.76 16. 6. or its equivalent. Application Cover Sheet Other: 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, 18. or in an Application Data Sheet under 37 CFR 1.76: of prior application No . 09/663,607 and 09/663,606 Continuation-in-part (CIP) Continuation Divisional Prior application information. Examiner Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS 23865 Correspondence address below Customer Number or Bar Code Label (Insert Customer No. or Attach b Jonathan L. Pettit Name Brobeck, Phleger & Harrison LLP 12390 El Camino Real Address Zip Code 92130-2081 State CA City San Diego Telephone 858/720-2500 Fax 858/720-2555 USA Country 40,770 Registration No. (Attorney/Agent) Name (Print/Type) Jonathan L. Pettit

SDILIB1\JB09\412375.01(412375_1.DOC)

Signature 5 4 1

PTO/SB/17 (10-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$)1,573.00

Complete if Known					
Application Number	To be assigned				
Filing Date	Herewit h				
First Named Inventor	Alan H. Ostroff				
Examiner Name	To be assigned				
Group Art Unit	To be assigned				
Attorney Docket No.	032580 0045 CIP				

METHOD OF PAYMENT				FEE CALCULATION (continued)							
Dep	fees and o	missioner credit and 50-1273	r is hereb overnav	y authorized to charg	e indicated	3. ADI	DITION/ Large Entity Fee	AL FEI	Small Entity Fee	Fee Description	Fee Paid
Nun						Code	(\$)	Code	(\$)		- CC Faid
Dep			-			105	130	205		Surcharge – late filing fee or oath	
Account Brobeck, Phleger & Harrison LLP				127	50	227	25	Surcharge – late provisional filing fee or cover sheet			
	Charge An Under 37 C			uired		139	130	139	130	Non-English specification	
	Applicant o	laıms smal		itus See		147	2,520	147	2,520	For filing a request for ex parte reexamination	
37 CFR 1 27 2. ⊠ Payment Enclosed:					112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
X	Check	☐ Cred		☐ Money Order ☐ CULATION	Other	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
1 12 4	SIC FILI					115	110	215	55	Extension for reply within first month	
	ge Entit		I Entity			116	400	216	200	Extension for reply within second month	
Fe Co	-		Fee (\$)	Fee Description	Fee Paid	117	920	217	460	Extension for reply within third month	
	01 740		370	Utility filing fee	370 00	118	1,440	218	720	Extension for reply within fourth month	
	06 33			Design filing fee		128	1,960	228	980	Extension for reply within fifth month	
1	07 51	0 207	255	Plant filing fee		119	320	219	160	Notice of Appeal	
	08 74			Reissue filing fee		120	320	220	160	Filing a brief in support of an appeal	
1	14 16	0 214	80	Provisional filing fee		121	280	221	140	Request for oral hearing	
SUBTOTAL (1) (\$)370.00			138	1,510	138	1,510	Petition to institute a public use proceeding				
2. EXTRA CLAIM FEES			140	110	240	55	Petition to revive – unavoidable				
Fee from				141	1,280	241	640	Petition to revive – unintentional			
Total C	laime 1		Extra Cla 20** = 129		Fee Paid = 1,161 00	142	1,280	242	640	Utility issue fee (or reissue)	
indepe	-		-3** = .		_	143	460	243	230	Design issue fee	
Claims	_ 4		1_	42.00	42.00	144	620	244	310	Plant issue fee	
-	Depend		Endle:			122	130	122	130	Petitions to the Commissioner	
Large Fee	Entity Fee	Small Fee	Entity Fee	Fee Descri	iption	123 126	50 180	123 126	50 180	Processing fee under 37 CFR 1.17(q) Submission of Information Disclosure Stmt	
Code 103	(\$)	Code 203	(\$) 9	Claims in excess of	20	581	40	581	40	Recording each patent assignment per	
103	18 84	203 202	42	Independent claims		440	740	040	270	property (times number of properties)	
104	280	204	140	Multiple dependent		146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
109	84	209	42	** Reissue independ over original patent	lent claims	149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
110	18	210	9	** Reissue claims in	excess of 20	179	740	279	370	Request for Continued Examination (RCE)	
110	10	210		and over original	patent	169	900	169	900	Request for expedited examination of a design application	
			SU	IBTOTAL (2) (\$)1	1,203.00	Other fo	ee (spec	ify)			
**or number previously paid, if greater; For Reissues, see above					*Reduc	ed by Ba	asic Filir	ng Fee F	Paid SUBTOTAL (3) (\$)		

SUBMITTED BY			Complete (if applicable)						
Name (Print/Type)	Jonathan L. Pettit	Λ	00.	Registration No. (Attorney/Agent)	40,770	Telephone	(858) 720-2500		
Signature	On	attan	150	w -		Date	11/5/01		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0 2 hours to complete. Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

CONTINUATION-IN-PART APPLICATION

UNDER 37 CFR § 1.53(b)

TITLE:

CURRENT WAVEFORMS FOR ANTI-TACHYCARDIA PACING FOR

A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-

DEFIBRILLATOR

APPLICANT(S):

OSTROFF, ALAN H.; RISSMAN, WILLIAM J.; MEZACK, GARY

R.

Correspondence Enclosed:

Utility Application Transmittal Sheet and FY 2001 Fee Transmittal Sheet (2pgs); Description (55pgs); Claims (35pgs); Abstract (1pg);

Drawings Figures 1-20 (11 sheets); Check in the amount of

\$1,573.00; and Return Postcard.

PRIORITY DATA:

Under 35 U.S.C. §120 this application claims the benefit of U.S. Patent Application Serial No. 09/663,607, filed September 18, 2001; U.S. Patent Application Serial No. 09/663,606, filed September 18, 2001; U.S. Patent Application entitled "Monophasic Waveform for

Anti-Bradycardia Pacing for a Subcutaneous Implantable

Cardioverter-Defibrillator", filed concurrently herewith; U.S. Patent Application entitled "Monophasic Waveform for Anti-Tachycardia Pacing for a Subcutaneous Implantable Cardioverter-Defibrillator", field concurrently herewith; and U.S. Patent Application entitled "Current Waveforms for Anti-Bradycardia Pacing for a Subcutaneous

Cardioverter-Defibrillator", filed concurrently herewith.

"EXPRESS MAIL" Mailing Label Number <u>EL675946346US</u> Date of Deposit <u>November 5, 2001</u> I hereby certify under 37 CFR §1.10 that this correspondence (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Josh Gibbs